Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$885.55 USD

885.55
1,972,736

-5.52 (-0.62%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.

Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity

Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $202.02, moving -0.34% from the previous trading session.

United Therapeutics (UTHR) Begins TETON Study on Tyvaso in IPF

United Therapeutics (UTHR) enrolls the first patient in the phase III TETON study evaluating Tyvaso for treating adult patients with idiopathic pulmonary fibrosis.

Regeneron (REGN) Stock Up 3.5% YTD: What's in Store for 2H21?

Regeneron's performance so far in the year has been good on the back of a solid product portfolio and an incremental contribution from the antibody cocktail.

Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment

Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.

Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention

The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.

Lilly (LLY) Up 11.3% Since Last Earnings Report: Can It Continue?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for May 27th

AFYA, BNL, CLBS, EKSO, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2021

Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod

Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.

Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC (Revised)

Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.

Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod

The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.

The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

Kinjel Shah headshot

Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints

Lilly's (LLY) Fifth Tirzepatide Study Meets All Key Endpoints

Lilly's (LLY) SURPASS-4 study evaluating tirzepatide against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk meets all primary and key secondary endpoints.

New Strong Sell Stocks for May 19th

ALBO, BFIN, GOOS, DKNG, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2021

Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC

Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.

New Strong Sell Stocks for May 13th

PRTS, CIGI, ELMD, LLY, and TTWO have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2021

Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

New Strong Sell Stocks for May 11th

PFPT, KLR, GDDY, LLY, and FUV have been added to the Zacks Rank #5 (Strong Sell) List on May 11, 2021

Radius (RDUS) Q1 Loss Narrower than Expected, Revenues Lag

Radius (RDUS) reports a narrower loss but misses on sales in the first quarter as lead drug sales decline.

United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat

United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) beat estimates for both earnings and sales in the first quarter of 2021.

Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi

Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.